Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.deciphera.com
Earnings Expectation
Deciphera Pharmaceuticals, Inc. is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.3 per share from revenue of $ 7.05 million. Looking ahead, the full year loss are expected at $ 5.22 per share on the revenues of $ 24.04 million.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The companys lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors.
